Octreotide Versus Octreotide Plus Interferon-Alpha in Endocrine Gastroenteropancreatic Tumors: A Randomized Trial  Rudolf Arnold, Anja Rinke, Klaus-Jochen Klose, Hans-Helge Müller, Matthias Wied, Karin Zamzow, Christina Schmidt, Carmen Schade- Brittinger, Peter Barth, Roland Moll, Michael Koller, Michael Unterhalt, Wolfgang Hiddemann, Martin Schmidt-Lauber, Marianne Pavel, Christian N. Arnold  Clinical Gastroenterology and Hepatology  Volume 3, Issue 8, Pages 761-771 (August 2005) DOI: 10.1016/S1542-3565(05)00481-7 Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 1 Trial profile. Clinical Gastroenterology and Hepatology 2005 3, 761-771DOI: (10.1016/S1542-3565(05)00481-7) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 2 Intention to treat analysis of survival in 51 patients receiving octreotide monotherapy (solid line) and in 54 patients receiving octreotide plus interferon alpha (dotted line). After 6 months 50% of patients in either group had an event terminating the study treatment (P = .59). Vertical lines (|) indicate censoring, which means after a patient’s last follow up, no further information on the patient was available. Clinical Gastroenterology and Hepatology 2005 3, 761-771DOI: (10.1016/S1542-3565(05)00481-7) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 3 Intention to treat analysis of survival in 51 patients receiving octreotide monotherapy (solid line) and in 54 patients receiving octreotide plus interferon-alpha (dotted line) (P = .38). Nine patients have not been randomized (broken line) (P = .083 vs randomized patients). Vertical lines (|) indicate censoring, which means after a patient’s last follow up, no further information on the patient was available. Clinical Gastroenterology and Hepatology 2005 3, 761-771DOI: (10.1016/S1542-3565(05)00481-7) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 4 Survival of 47 patients with stable disease before randomization of >6 months (solid line) versus 66 patients with stable disease before randomization of ≤6 months (dotted line). (Exploratory analysis, P = .06.) Vertical lines (|) indicate censoring, which means after a patient’s last follow up, no further information on the patient was available. Clinical Gastroenterology and Hepatology 2005 3, 761-771DOI: (10.1016/S1542-3565(05)00481-7) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 5 Survival of 31 patients with stable disease or partial regression at 6 months of treatment with monotherapy or combination treatment (solid line) versus survival in 44 patients with tumor progression (dotted line). (P = .0057). Vertical lines (|) indicate censoring, which means after a patient’s last follow up, no further information on the patient was available. Clinical Gastroenterology and Hepatology 2005 3, 761-771DOI: (10.1016/S1542-3565(05)00481-7) Copyright © 2005 American Gastroenterological Association Terms and Conditions

Figure 6 Survival of 37 patients with low Ki-67 (solid line) versus 31 patients with high Ki-67 (broken line). (P = .0292). Vertical lines (|) indicate censoring, which means after a patient’s last follow up, no further information on the patient was available. Clinical Gastroenterology and Hepatology 2005 3, 761-771DOI: (10.1016/S1542-3565(05)00481-7) Copyright © 2005 American Gastroenterological Association Terms and Conditions